Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.81
- Piotroski Score 1.00
- Grade Neutral
- Symbol (HILS)
- Company Hillstream BioPharma, Inc.
- Price $0.24
- Changes Percentage (5.66%)
- Change $0.01
- Day Low $0.22
- Day High $0.24
- Year High $2.65
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.70
- Trailing P/E Ratio -0.33857142857143
- Forward P/E Ratio -0.33857142857143
- P/E Growth -0.33857142857143
- Net Income $-9,319,094
Income Statement
Quarterly
Annual
Latest News of HILS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why We Think Hill & Smith (LON:HILS) Is Well Worth Watching
Investors are attracted to turnaround companies despite risks. Traditional investors prefer profitable companies like Hill & Smith. With growing earnings and revenue, Hill & Smith is adding long-term ...
By Yahoo! Finance | 3 weeks ago -
Hill & Smith's (LON:HILS) five-year total shareholder returns outpace the underlying earnings growth
Stock pickers seek stocks that outperform the market. Hill & Smith's shares surged 70% in 5 years, outpacing the market return of 2.3%. Recent returns show a 19% increase, indicating potential busines...
By Yahoo! Finance | 2 months ago -
LeMahieu has career-high 6 RBIs, Yanks beat Phils 6-5 for 3-game sweep and 5-game winning streak
DJ LeMahieu's six RBIs, including a grand slam, led the Yankees to a 6-5 win over the Phillies, extending their winning streak to five games. Nestor Cortes earned his first road win of the season. Phi...
By AP NEWS | 3 months ago
